Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at Leerink Swann cut their FY2018 EPS estimates for Alnylam Pharmaceuticals in a research note issued to investors on Wednesday. Leerink Swann analyst P. Matteis now forecasts that the biopharmaceutical company will earn ($5.58) per share for the year, down from their previous forecast of ($5.02). Leerink Swann has a “Market Perform” rating and a $72.00 price target on the stock.

Several other analysts have also recently commented on the stock. Goldman Sachs Group, Inc. (The) upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $62.00 to $163.00 in a report on Monday, October 2nd. Jefferies Group LLC lifted their target price on shares of Alnylam Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Tuesday, September 26th. Chardan Capital reiterated a “buy” rating and issued a $124.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, September 25th. BMO Capital Markets reiterated an “outperform” rating and issued a $134.00 target price (up from $99.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, September 22nd. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $146.00 target price (up from $90.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 21st. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $100.80.

ILLEGAL ACTIVITY NOTICE: “Brokers Set Expectations for Alnylam Pharmaceuticals, Inc.’s FY2018 Earnings (ALNY)” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/27/brokers-set-expectations-for-alnylam-pharmaceuticals-inc-s-fy2018-earnings-alny.html.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) traded up 4.74% during trading on Friday, reaching $119.92. 1,459,095 shares of the company traded hands. The firm has a 50-day moving average price of $107.11 and a 200-day moving average price of $81.44. The firm’s market capitalization is $11.00 billion. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $126.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. During the same period last year, the company posted ($1.05) EPS. The business’s revenue for the quarter was up 82.9% on a year-over-year basis.

A number of hedge funds have recently made changes to their positions in ALNY. Parametric Portfolio Associates LLC increased its position in Alnylam Pharmaceuticals by 71.2% during the first quarter. Parametric Portfolio Associates LLC now owns 60,030 shares of the biopharmaceutical company’s stock worth $3,077,000 after acquiring an additional 24,967 shares during the period. JPMorgan Chase & Co. increased its position in Alnylam Pharmaceuticals by 11.9% during the first quarter. JPMorgan Chase & Co. now owns 62,986 shares of the biopharmaceutical company’s stock worth $3,228,000 after acquiring an additional 6,678 shares during the period. Prudential Financial Inc. bought a new position in Alnylam Pharmaceuticals during the first quarter worth $215,000. Teachers Advisors LLC increased its position in Alnylam Pharmaceuticals by 9.1% during the first quarter. Teachers Advisors LLC now owns 80,238 shares of the biopharmaceutical company’s stock worth $4,112,000 after acquiring an additional 6,662 shares during the period. Finally, PNC Financial Services Group Inc. increased its position in Alnylam Pharmaceuticals by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 8,685 shares of the biopharmaceutical company’s stock worth $446,000 after acquiring an additional 36 shares during the period. 94.25% of the stock is currently owned by institutional investors and hedge funds.

In related news, President Barry E. Greene sold 85,316 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Barry E. Greene sold 76,815 shares of the business’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.